NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD
3.31
+0.03 (+0.91%)
The current stock price of ELDN is 3.31 USD. In the past month the price increased by 4.75%. In the past year, price increased by 37.34%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
ELEDON PHARMACEUTICALS INC
19800 Macarthur Blvd., Suite 250
Irvine CALIFORNIA 92612 US
CEO: David-Alexandre C. Gros
Employees: 20
Phone: 19492388090
The current stock price of ELDN is 3.31 USD. The price increased by 0.91% in the last trading session.
The exchange symbol of ELEDON PHARMACEUTICALS INC is ELDN and it is listed on the Nasdaq exchange.
ELDN stock is listed on the Nasdaq exchange.
12 analysts have analysed ELDN and the average price target is 10.61 USD. This implies a price increase of 220.48% is expected in the next year compared to the current price of 3.31. Check the ELEDON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELEDON PHARMACEUTICALS INC (ELDN) has a market capitalization of 198.20M USD. This makes ELDN a Micro Cap stock.
ELEDON PHARMACEUTICALS INC (ELDN) currently has 20 employees.
ELEDON PHARMACEUTICALS INC (ELDN) has a support level at 3.15 and a resistance level at 3.39. Check the full technical report for a detailed analysis of ELDN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELDN does not pay a dividend.
ELEDON PHARMACEUTICALS INC (ELDN) will report earnings on 2025-05-08.
ELEDON PHARMACEUTICALS INC (ELDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).
The outstanding short interest for ELEDON PHARMACEUTICALS INC (ELDN) is 3.03% of its float. Check the ownership tab for more information on the ELDN short interest.
ChartMill assigns a technical rating of 2 / 10 to ELDN. When comparing the yearly performance of all stocks, ELDN is one of the better performing stocks in the market, outperforming 76.19% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ELDN. ELDN has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS increased by 41.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -33.72% | ||
ROE | -50.63% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to ELDN. The Buy consensus is the average rating of analysts ratings from 12 analysts.